Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

This study is investigating whether certain breast cancer patients can safely skip part of the white blood cell booster shots (G-CSF, such as Neulasta) given during a specific phase of dense-dose chemotherapy (the paclitaxel portion), without increasing the risk of serious infection. **You may be eligible if...** - You have early-stage or locally advanced breast cancer - You are receiving dose-dense AC/T chemotherapy (a common breast cancer regimen) as either pre- or post-surgery treatment - You require G-CSF prophylaxis as part of your chemotherapy plan - You can complete questionnaires in English or French **You may NOT be eligible if...** - You have metastatic breast cancer - You have a known allergy to filgrastim or pegfilgrastim - You do not have access to the required G-CSF medications before starting treatment Talk to your doctor to see if this trial is right for you.